Title : CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?

Pub. Date : 2018 Dec

PMID : 29876704






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 OBJECTIVE: To identify a reliable early indicator of deriving progression-free survival (PFS) benefit in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with octreotide long-acting repeatable (LAR). Octreotide granulin precursor Homo sapiens
2 CONCLUSION: A 10% shrinkage in tumor size is an optimal early predictor of response to octreotide LAR in advanced GEP-NETs. Octreotide granulin precursor Homo sapiens
3 Ten percent tumor shrinkage is a reliable indicator of the response to octreotide for advanced GEP-NETs. Octreotide granulin precursor Homo sapiens